Outcomes of patients who developed subsequent solid cancer after Hematopoietic cell transplantation

Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

To characterize the outcomes of patients who developed a particular subsequent solid cancer after hematopoietic cell transplantation (HCT), age at cancer diagnosis, survival, and causes of death were compared with the respective primary cancer in the general population, using data from the national HCT registry and population-based cancer registries in Japan. Among 31 867 patients who underwent a first HCT between 1990 and 2013 and had progression-free survival at 1 year, 713 patients developed subsequent solid cancer. The median age at subsequent solid cancer diagnosis was 55 years, which was significantly younger than the 67 years for primary cancer patients in the general population (P, .001). The overall survival probability was 60% at 3 years after diagnosis of subsequent solid cancer and differed according to cancer type. Development of most solid cancers was associated with an increased risk of subsequent mortality after HCT. Subsequent solid cancers accounted for 76% of causes of death. Overall survival probabilities adjusted for age, sex, and year of diagnosis were lower in the HCT population than in the general population for colon, bone/soft tissue, and central nervous system cancers and did not differ statistically for other cancers. In conclusion, most subsequent solid cancers occurred at younger ages than primary cancers, emphasizing the need for cancer screening at younger ages. Subsequent solid cancers showed similar or worse survival compared with primary cancers. Biological and genetic differences between primary and subsequent solid cancers remain to be determined.

Original languageEnglish
Pages (from-to)1901-1913
Number of pages13
JournalBlood Advances
Volume2
Issue number15
DOIs
Publication statusPublished - Aug 14 2018

Fingerprint

Cell Transplantation
Neoplasms
Survival
Population
Registries
Cause of Death

ASJC Scopus subject areas

  • Hematology

Cite this

Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group (2018). Outcomes of patients who developed subsequent solid cancer after Hematopoietic cell transplantation. Blood Advances, 2(15), 1901-1913. https://doi.org/10.1182/bloodadvances.2018020966

Outcomes of patients who developed subsequent solid cancer after Hematopoietic cell transplantation. / Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group.

In: Blood Advances, Vol. 2, No. 15, 14.08.2018, p. 1901-1913.

Research output: Contribution to journalArticle

Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group 2018, 'Outcomes of patients who developed subsequent solid cancer after Hematopoietic cell transplantation', Blood Advances, vol. 2, no. 15, pp. 1901-1913. https://doi.org/10.1182/bloodadvances.2018020966
Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group. Outcomes of patients who developed subsequent solid cancer after Hematopoietic cell transplantation. Blood Advances. 2018 Aug 14;2(15):1901-1913. https://doi.org/10.1182/bloodadvances.2018020966
Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group. / Outcomes of patients who developed subsequent solid cancer after Hematopoietic cell transplantation. In: Blood Advances. 2018 ; Vol. 2, No. 15. pp. 1901-1913.
@article{961430f16b0b4769b46e6d3625ea9d9f,
title = "Outcomes of patients who developed subsequent solid cancer after Hematopoietic cell transplantation",
abstract = "To characterize the outcomes of patients who developed a particular subsequent solid cancer after hematopoietic cell transplantation (HCT), age at cancer diagnosis, survival, and causes of death were compared with the respective primary cancer in the general population, using data from the national HCT registry and population-based cancer registries in Japan. Among 31 867 patients who underwent a first HCT between 1990 and 2013 and had progression-free survival at 1 year, 713 patients developed subsequent solid cancer. The median age at subsequent solid cancer diagnosis was 55 years, which was significantly younger than the 67 years for primary cancer patients in the general population (P, .001). The overall survival probability was 60{\%} at 3 years after diagnosis of subsequent solid cancer and differed according to cancer type. Development of most solid cancers was associated with an increased risk of subsequent mortality after HCT. Subsequent solid cancers accounted for 76{\%} of causes of death. Overall survival probabilities adjusted for age, sex, and year of diagnosis were lower in the HCT population than in the general population for colon, bone/soft tissue, and central nervous system cancers and did not differ statistically for other cancers. In conclusion, most subsequent solid cancers occurred at younger ages than primary cancers, emphasizing the need for cancer screening at younger ages. Subsequent solid cancers showed similar or worse survival compared with primary cancers. Biological and genetic differences between primary and subsequent solid cancers remain to be determined.",
author = "{Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group} and Yoshihiro Inamoto and Tomohiro Matsuda and Ken Tabuchi and Saiko Kurosawa and Hideki Nakasone and Hisakazu Nishimori and Satoshi Yamasaki and Noriko Doki and Koji Iwato and Takehiko Mori and Satoshi Takahashi and Hiromasa Yabe and Akio Kohno and Hirohisa Nakamae and Toru Sakura and Hisako Hashimoto and Junichi Sugita and Hiroatsu Ago and Takahiro Fukuda and Tatsuo Ichinohe and Yoshiko Atsuta and Takuya Yamashita and Minako Iida and Takayuki Ishikawa and Keiichi Isoyama and Masami Inoue and Kumi Oshima and Shinichiro Okamoto and Rika Sakai and Masaaki Shiohara and Shuichi Taniguchi and H. Nakasone and Makoto Hirokawa and Shin Fujisawa and Yasuo Horikoshi and Masato Masuda and Hidetsugu Mihara and Yuki Asano-Mori and Yasushi Ishida and Aika Seto and Nahoko Hatsumi and Akira Hayakawa and Atsushi Sato and H. Nishimori and Masako Toyosaki and Koichi Miyamura and Chikako Kiyotani and Raine Tatara and Toshihiro Matsukawa and Satoshi Yoshioka",
year = "2018",
month = "8",
day = "14",
doi = "10.1182/bloodadvances.2018020966",
language = "English",
volume = "2",
pages = "1901--1913",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "15",

}

TY - JOUR

T1 - Outcomes of patients who developed subsequent solid cancer after Hematopoietic cell transplantation

AU - Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group

AU - Inamoto, Yoshihiro

AU - Matsuda, Tomohiro

AU - Tabuchi, Ken

AU - Kurosawa, Saiko

AU - Nakasone, Hideki

AU - Nishimori, Hisakazu

AU - Yamasaki, Satoshi

AU - Doki, Noriko

AU - Iwato, Koji

AU - Mori, Takehiko

AU - Takahashi, Satoshi

AU - Yabe, Hiromasa

AU - Kohno, Akio

AU - Nakamae, Hirohisa

AU - Sakura, Toru

AU - Hashimoto, Hisako

AU - Sugita, Junichi

AU - Ago, Hiroatsu

AU - Fukuda, Takahiro

AU - Ichinohe, Tatsuo

AU - Atsuta, Yoshiko

AU - Yamashita, Takuya

AU - Iida, Minako

AU - Ishikawa, Takayuki

AU - Isoyama, Keiichi

AU - Inoue, Masami

AU - Oshima, Kumi

AU - Okamoto, Shinichiro

AU - Sakai, Rika

AU - Shiohara, Masaaki

AU - Taniguchi, Shuichi

AU - Nakasone, H.

AU - Hirokawa, Makoto

AU - Fujisawa, Shin

AU - Horikoshi, Yasuo

AU - Masuda, Masato

AU - Mihara, Hidetsugu

AU - Asano-Mori, Yuki

AU - Ishida, Yasushi

AU - Seto, Aika

AU - Hatsumi, Nahoko

AU - Hayakawa, Akira

AU - Sato, Atsushi

AU - Nishimori, H.

AU - Toyosaki, Masako

AU - Miyamura, Koichi

AU - Kiyotani, Chikako

AU - Tatara, Raine

AU - Matsukawa, Toshihiro

AU - Yoshioka, Satoshi

PY - 2018/8/14

Y1 - 2018/8/14

N2 - To characterize the outcomes of patients who developed a particular subsequent solid cancer after hematopoietic cell transplantation (HCT), age at cancer diagnosis, survival, and causes of death were compared with the respective primary cancer in the general population, using data from the national HCT registry and population-based cancer registries in Japan. Among 31 867 patients who underwent a first HCT between 1990 and 2013 and had progression-free survival at 1 year, 713 patients developed subsequent solid cancer. The median age at subsequent solid cancer diagnosis was 55 years, which was significantly younger than the 67 years for primary cancer patients in the general population (P, .001). The overall survival probability was 60% at 3 years after diagnosis of subsequent solid cancer and differed according to cancer type. Development of most solid cancers was associated with an increased risk of subsequent mortality after HCT. Subsequent solid cancers accounted for 76% of causes of death. Overall survival probabilities adjusted for age, sex, and year of diagnosis were lower in the HCT population than in the general population for colon, bone/soft tissue, and central nervous system cancers and did not differ statistically for other cancers. In conclusion, most subsequent solid cancers occurred at younger ages than primary cancers, emphasizing the need for cancer screening at younger ages. Subsequent solid cancers showed similar or worse survival compared with primary cancers. Biological and genetic differences between primary and subsequent solid cancers remain to be determined.

AB - To characterize the outcomes of patients who developed a particular subsequent solid cancer after hematopoietic cell transplantation (HCT), age at cancer diagnosis, survival, and causes of death were compared with the respective primary cancer in the general population, using data from the national HCT registry and population-based cancer registries in Japan. Among 31 867 patients who underwent a first HCT between 1990 and 2013 and had progression-free survival at 1 year, 713 patients developed subsequent solid cancer. The median age at subsequent solid cancer diagnosis was 55 years, which was significantly younger than the 67 years for primary cancer patients in the general population (P, .001). The overall survival probability was 60% at 3 years after diagnosis of subsequent solid cancer and differed according to cancer type. Development of most solid cancers was associated with an increased risk of subsequent mortality after HCT. Subsequent solid cancers accounted for 76% of causes of death. Overall survival probabilities adjusted for age, sex, and year of diagnosis were lower in the HCT population than in the general population for colon, bone/soft tissue, and central nervous system cancers and did not differ statistically for other cancers. In conclusion, most subsequent solid cancers occurred at younger ages than primary cancers, emphasizing the need for cancer screening at younger ages. Subsequent solid cancers showed similar or worse survival compared with primary cancers. Biological and genetic differences between primary and subsequent solid cancers remain to be determined.

UR - http://www.scopus.com/inward/record.url?scp=85069272901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069272901&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018020966

DO - 10.1182/bloodadvances.2018020966

M3 - Article

C2 - 30087108

AN - SCOPUS:85069272901

VL - 2

SP - 1901

EP - 1913

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 15

ER -